[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Bristol-Myers Squibb Stock Underperforming the Dow?

Valued at a market cap of $112.2 billion, Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products. The Princeton, New Jersey-based company offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.

Companies worth $10 billion or more are typically classified as “large-cap stocks,” and BMY fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers - general industry. The company's core specialty lies in its pioneering leadership across high-barrier therapeutic areas, specifically oncology, hematology, cardiovascular disease, and immunology, while aggressively expanding into next-generation...

Fundamentals

See More
  • Market Capitalization, $K 1,002,153,728
  • Shares Outstanding, K 941,741
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 31,522 M
  • EBITDA $ 33,519 M
  • 60-Month Beta 0.53
  • Price/Sales 15.64
  • Price/Cash Flow 43.96
  • Price/Book 33.35

Options Overview Details

View History
  • Implied Volatility 34.48% (+0.59%)
  • Historical Volatility 41.53%
  • IV Percentile 37%
  • IV Rank 36.58%
  • IV High 47.67% on 07/30/25
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 2) 27.47 (2.58%)
  • Put/Call Vol Ratio 0.81
  • Today's Volume 38,717
  • Volume Avg (30-Day) 45,861
  • Put/Call OI Ratio 1.08
  • Today's Open Interest 353,534
  • Open Int (30-Day) 343,201
  • Expected Range 1,036.68 to 1,091.62

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $8.84
  • Number of Estimates 7
  • High Estimate $9.26
  • Low Estimate $7.83
  • Prior Year $6.31
  • Growth Rate Est. (year over year) +40.10%

Price Performance

See More
Period Period Low Period High Performance
1-Month
943.26 +12.82%
on 05/11/26
1,149.10 -7.39%
on 05/28/26
+100.82 (+10.47%)
since 05/01/26
3-Month
850.51 +25.12%
on 04/29/26
1,149.10 -7.39%
on 05/28/26
+46.18 (+4.54%)
since 03/02/26
52-Week
623.78 +70.60%
on 08/08/25
1,149.10 -7.39%
on 05/28/26
+317.03 (+42.43%)
since 06/02/25

Most Recent Stories

More News
Is Bristol-Myers Squibb Stock Underperforming the Dow?

Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.

LLY : 1,064.15 (-1.67%)
$DOWI : 51,307.79 (+0.45%)
BMY : 54.46 (-0.89%)
Even If Eli Lilly Stock Continues to Shine, Stay Away from This Pharmaceutical ETF

The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.

IHE : 88.99 (-1.44%)
JNJ : 222.89 (-0.28%)
LLY : 1,064.15 (-1.67%)
PPH : 101.22 (-1.04%)
$DOWI : 51,307.79 (+0.45%)
Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

Positive results from the Phase 3 BRUIN CLL-322 study comparing time-limited pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory CLL/SLL...

LLY : 1,064.15 (-1.67%)
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Phase 3 LIBRETTO-432 results establish RET fusions alongside EGFR mutations and ALK fusions as biomarkers in early-stage lung cancer that are associated with dramatic treatment outcomes, underscoring the...

LLY : 1,064.15 (-1.67%)
5 Best Growth Stocks for the Next 10 Years

These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade

MELI : 1,672.83 (-3.36%)
AAPL : 315.20 (+2.90%)
AVGO : 481.57 (+4.70%)
NVO : 42.92 (-2.61%)
LLY : 1,064.15 (-1.67%)
NET : 272.66 (+0.68%)
TSM : 446.69 (+2.54%)
Why Eli Lilly (LLY) Stock Is Trading Up Today

Why Eli Lilly (LLY) Stock Is Trading Up Today

LLY : 1,064.15 (-1.67%)
Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

Phase 3 ACHIEVE results showed Foundayo, an oral GLP-1 taken without food or water restrictions, outperformed oral semaglutide and dapagliflozin in type 2 diabetes, reinforcing its potential to...

LLY : 1,064.15 (-1.67%)
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?

Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes.

HIMS : 27.51 (-0.90%)
NVO : 42.92 (-2.61%)
LLY : 1,064.15 (-1.67%)
ABBV : 215.40 (+1.16%)
Is Eli Lilly Stock Outperforming the Nasdaq?

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

$NASX : 27,093.90 (+0.03%)
JNJ : 222.89 (-0.28%)
LLY : 1,064.15 (-1.67%)
Foundayo and Zepbound now covered for millions of Americans

CVS Caremark begins covering Foundayo June 1 and resumes Zepbound coverage by October 1

LLY : 1,064.15 (-1.67%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,103.60
2nd Resistance Point 1,090.91
1st Resistance Point 1,077.53
Last Price 1,064.15
1st Support Level 1,051.46
2nd Support Level 1,038.77
3rd Support Level 1,025.39

See More

52-Week High 1,149.10
Last Price 1,064.15
Fibonacci 61.8% 948.43
Fibonacci 50% 886.44
Fibonacci 38.2% 824.45
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.